Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

This is the primary report of the large-scale evaluation of lotrafiban, an orally administered IIb/IIIa receptor antagonist, a unique trial with respect to the platelet antagonist, protocol design, and inclusion of cerebrovascular disease in a significant proportion of patients. Patients with vascul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2003-07, Vol.108 (4), p.399-406
Hauptverfasser:	Topol, Eric J, Easton, Donald, Harrington, Robert A, Amarenco, Pierre, Califf, Robert M, Graffagnino, Carmen, Davis, Stephen, Diener, Hans-Christophe, Ferguson, James, Fitzgerald, Desmond, Granett, Jeffrey, Shuaib, Ashfaq, Koudstaal, Peter J, Theroux, Pierre, Van de Werf, Frans, Sigmon, Kristina, Pieper, Karen, Vallee, Marc, Willerson, James T
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Aspirin - adverse effects Aspirin - therapeutic use Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Cerebrovascular Disorders - drug therapy Cerebrovascular Disorders - mortality Coronary Disease - drug therapy Coronary Disease - mortality Creatinine - blood Creatinine - urine Dose-Response Relationship, Drug Double-Blind Method Female Follow-Up Studies Hemorrhage - chemically induced Humans Male Middle Aged Multivariate Analysis Piperidines - adverse effects Piperidines - therapeutic use Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Proportional Hazards Models Risk Assessment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!